Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294853 | 0.87 | RORC (0.42) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL20584659 | 0.87 | RORC (0.42) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL20446551 | 0.87 | RORC (0.42) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL17294854 | 0.87 | RORC (0.42) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL12166405 | 0.87 | RORC (0.42) | RORCNR1H2NR1H3GPR119 | |
| SCHEMBL12880874 | 0.85 | NR1H2 (0.40) | RORCNR1H2NR1H3GPR119RXRA | |
| SCHEMBL21430555 | 0.84 | F10 (0.38) | RORCNR1H2NR1H3 | |
| SCHEMBL25360071 | 0.83 | OPRK1 (0.41) | RORC | |
| SCHEMBL12166384 | 0.82 | RORC (0.41) | KMT2ARORCMEN1 | |
| SCHEMBL10992037 | 0.82 | KDM4E (0.44) | KMT2AKDM4EGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888464-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-7592336-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274648-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, PYGL | KMT2A 4486/4885RORC 429/4885MEN1 4801/4885 |
| US-20080152619-A1 | N-(4,6-dimethyl-2-pyridinyl)-L-valyl-(4R) N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-4-((6-methoxy-1-isoquinolinyl)oxy)-L-prolinamide; viricide; synergistic with other active ingredients | PREP, PPIL4, PPID | KMT2A 3698/4885RORC 3611/4885MEN1 4728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.